New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 30, 2014
10:00 EDTUAL, STBA, OSK, YRCW, TWTR, RRTS, INVN, WIN, SEIC, PRU, ICPT, IBTX, FSL, FNGN, FNFV, DSX, CHRW, RESI, AUOOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: AU Optronics (AUO) upgraded to Buy from Sell at Citigroup... Altisource Residential (RESI) upgraded to Outperform at Keefe Bruyette... C.H. Robinson (CHRW) upgraded to Neutral from Underperform at BofA/Merrill... Diana Shipping (DSX) upgraded to Buy from Hold at Stifel... Fidelity National Financial Ventures (FNFV) upgraded to Overweight from Equal Weight at Stephens... Financial Engines (FNGN) upgraded to Market Perform from Underperform at Raymond James... Freescale (FSL) upgraded to Equal Weight from Underweight at Morgan Stanley... Independent Bank (IBTX) upgraded to Outperform from Neutral at Macquarie... Intercept (ICPT) upgraded at Nomura... Internap (INAP) upgraded to Outperform from Market Perform at Cowen... InvenSense (INVN) upgraded to Buy from Hold at Ascendiant... Oshkosh (OSK) upgraded to Outperform from Neutral at RW Baird... Prudential (PRU) upgraded to Buy from Hold at Canaccord... Roadrunner (RRTS) upgraded to Outperform from Market Perform at Raymond James... S&T Bancorp (STBA) upgraded to Neutral from Sell at Guggenheim... SEI Investments (SEIC) upgraded at Oppenheimer... Twitter (TWTR) upgraded to Neutral from Sell at UBS... United Continental (UAL) upgraded to Overweight from Neutral at JPMorgan... Windstream (WIN) upgraded to Buy from Neutral at DA Davidson... YRC Worldwide (YRCW) upgraded to Market Perform from Underperform at Raymond James.
News For AUO;RESI;CHRW;DSX;FNFV;FNGN;FSL;IBTX;ICPT;INVN;OSK;PRU;RRTS;STBA;SEIC;TWTR;UAL;WIN;YRCW From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | all recent news | >>
November 12, 2014
11:55 EDTICPTIntercept not part of talks with journals, says Deutsche Bank
Subscribe for More Information
10:08 EDTRESIAltisource Residential downgraded to Sell from Buy at Compass Point
09:37 EDTTWTRActive equity options trading
Active equity options trading according to Track Data: AAPL CLSN TWTR BABA NFLX TSLA AMZN CSIQ C
08:12 EDTOSKOshkosh remains a top machinery idea, says RW Baird
Subscribe for More Information
08:05 EDTCHRWGoldman to hold a conference
Subscribe for More Information
06:37 EDTTWTRTwitter weekly volatility increases into analyst day
Subscribe for More Information
November 11, 2014
16:01 EDTTWTROptions Update; November 11, 2014
Subscribe for More Information
12:00 EDTICPTIntercept results said to be rejected by New England Journal, Bloomberg says
Subscribe for More Information
11:29 EDTTWTRTwitter weekly volatility elevated into Financial Analyst Day
Subscribe for More Information
11:09 EDTTWTRTwitter to hold financial analyst day
Subscribe for More Information
10:00 EDTDSXOn The Fly: Analyst Initiation Summary
Subscribe for More Information
09:37 EDTTWTRActive equity options trading
Subscribe for More Information
November 10, 2014
18:15 EDTTWTRTwitter CEO, others sell $10.58M shared in planned sale, Barron's says
Subscribe for More Information
17:34 EDTUALUnited Continental October consolidated traffic up 0.4%
UAL's October 2014 consolidated traffic increased 0.4% and consolidated capacity increased 0.7% versus October 2013. UAL's October 2014 consolidated load factor decreased 0.2 points compared to October 2013.
16:13 EDTDSXDiana Shipping initiated with a Neutral at Sterne Agee
Subscribe for More Information
16:00 EDTTWTROptions Update; November 10, 2014
Subscribe for More Information
08:36 EDTICPTIntercept price target lowered to $125 from $172 at FBR Capital
FBR Capital lowered its price target for Intercept shares to $125 saying its talks with experts and cardiologists indicate the company's OCA drug is unlikely to be a "silver bullet" for the treatment of nonalcoholic steatohepatitis. FBR notes that while OCA appears to improve the liver, the drug worsens many of the other derangements like lipid and glucose homeostasis. FBR decreased the probability of success in NASH to 55% from 60%, and lowered its peak OCA sales estimate to $5.2B. It keeps an Underperform rating on Intercept shares.
07:23 EDTFSLRBC Capital to hold a conference
Subscribe for More Information
07:12 EDTTWTRCA Technologies to hold a conference
CA World 2014 is being held in Las Vegas on November 9-12.
November 9, 2014
11:56 EDTICPTIntercept announces additional data for OCA in primary biliary cirrhosis
Intercept Pharmaceuticals announced new analyses of data from clinical trials on obeticholic acid, OCA, in patients with primary biliary cirrhosis, PBC. Six posters, including posters with new analyses of data from POISE the first Phase 3 trial in PBC in two decades are being presented at today's poster session at the American Association for the Study of Liver Disease, AASLD, Annual Meeting. OCA, Intercept's lead product candidate, is a bile acid analog and first-in-class agonist of the farnesoid X receptor, FXR, in development for PBC, nonalcoholic steatohepatitis, NASH, primary sclerosing cholangitis, PSC, and other chronic liver diseases.
1 | 2 | 3 | 4 | 5 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use